Table 1

Subject demographics at baseline and final (after 6 months of therapy) visits

Exenatide (n = 14)Sitagliptin (n = 12)Glimepiride (n = 14)
Baseline6 monthsaΔBaseline6 monthsaΔBaseline6 monthsaΔ
Age (years)57 ± 257 ± 352 ± 3
Sex (% female)363343
Race (% African American)504264
Duration of T2D (years)3.3 ± 0.65.3 ± 1.73.4 ± 0.9
BMI (kg/m2)33 ± 232 ± 2*−1 ± 033 ± 133 ± 10 ± 031 ± 231 ± 20 ± 1
HbA1c, %b (mmol/mol)6.4 ± 0.1 (46)6.2 ± 0.1 (44)−0.2 ± 0.16.5 ± 0.1 (48)6.5 ± 0.2 (48)−0.01 ± 0.16.7 ± 0.1 (50)6.2 ± 0.2 (44)*−0.5 ± 0.2
Fasting glucose (mg/dL)129 ± 3128 ± 5−2 ± 5131 ± 4132 ± 81 ± 9134 ± 4126 ± 5−8 ± 6
Fasting insulin (μU/mL)24 ± 621 ± 3−3 ± 417 ± 214 ± 2−2.6 ± 217 ± 215 ± 1.3−2 ± 2
Fasting glucagon (pg/mL)40 ± 442 ± 82 ± 650 ± 647 ± 7−3 ± 651 ± 451 ± 5−0.2 ± 4
Total cholesterol (mg/dL)168 ± 7157 ± 6−10 ± 7159 ± 12162 ± 104 ± 6172 ± 10168 ± 11−4 ± 7
Triglycerides (mg/dL)110 ± 1585 ± 9−25 ± 14104 ± 17118 ± 2011 ± 10107 ± 1893 ± 11−14 ± 16
LDL cholesterol (mg/dL)104 ± 592 ± 6−12 ± 694 ± 10101 ± 95 ± 6110 ± 7111 ± 112 ± 7
HDL cholesterol (mg/dL)41 ± 248 ± 3*7 ± 244 ± 538 ± 2−3 ± 141 ± 338 ± 2−3 ± 2
  • Data are means ± SE.

  • Δ, change from baseline to 6 months with each value.

  • aFinal visits after 6 months of therapy were conducted following a 5- to 7-day drug washout.

  • bTo convert to mmol/mol, multiply by 10.93 and subtract 23.50.

  • *P < 0.05 when comparing values within each group.

  • P < 0.05 when comparing Δ between the exenatide and glimepiride groups.